20
Emcure Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DOLUTEGRAVIR SODIUM, with a corresponding US DMF Number 33140.
Remarkably, this DMF maintains an Active status since its submission on September 24, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 01, 2019, and payment made on January 30, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II